register

News - MedTech & Diagnostics

Surgical procedure to restore upper limb function after stroke

Health Industry Hub | April 30, 2021 |

MedTeh News: According to the World Health Organisation (WHO), 15 million people suffer stroke worldwide each year. Of these, approximately 80% lose upper limb function and as many as 50-60% of this population still experience problems six months later.

Traditionally, stroke patients try to regain motor function through physical rehabilitation, where patients re-learn pre-stroke skills, such as eating motions and grasping. However, most patients eventually plateau and stop improving over time.

Now, results of a clinical trial published in The Lancet gives patients new hope in their recovery.

Patients who received a novel treatment that combines MicroTransponder’s nerve stimulation (VNS) and rehabilitation showed improvement in upper body motor impairment compared to those who received sham (inactive form of) stimulation and rehabilitation.

“This is incredibly exciting news for everyone involved in stroke rehabilitation and functional restoration and represents a unique intersection between neurosurgery and neurorehabilitation,” said Charles Liu, MD, PhD, the lead neurosurgeon of the study and director of the USC Neurorestoration Centre of Keck Medicine of USC.

“These study results are the first of their kind, and open up new possibilities for stroke patients, allowing them to reclaim more arm function even years after having a stroke,” he added.

In the clinical trial, those receiving the nerve stimulation had a wire inserted into their neck that wrapped around the vagus nerve. The wire was then connected to a pulse generator device implanted in the chest. Those receiving the sham received placebo implants.

After the surgical procedure, all patients received six weeks of in-clinic therapy, which included tasks such as reaching and grasping, simulated eating and opening and closing containers. After the in-clinic period, patients continued treatment with a course of daily home therapy.

When the two patient groups were compared, those receiving the nerve stimulation scored higher on several standardised measures of upper arm functionality.

“Not only were the results clinically meaningful, the fact that these patients were at least nine months post-stroke and in some instances years out, points to the possibility that meaningful improvements can be achieved even years after a stroke,” said Liu, who also serves as chief of innovation and research and chair of neurosurgery and orthopaedics at Rancho Los Amigos National Rehabilitation Centre.

The device is thought to work by triggering the release of brain neuromodulators to strengthen motor circuits in the brain associated with movement, enabling the brain to effectively relearn tasks. VNS is already used widely for the treatment of epilepsy and plays an increasing role in the treatment of severe depression.

“For too long, stroke patients have faced limited options for recovery,” said Liu. “This new treatment signifies a breakthrough that could be life-changing for many stroke patients and also represents an approach that will certainly be explored for many other functional restoration applications in the future.”


News - MedTech & Diagnostics

‘Get comfortable being uncomfortable,’ urges Medtronic VP and Managing Director

Health Industry Hub | August 7, 2026 |

The leadership compass is being recalibrated as the old coordinates give way to complexity, contradiction and change. For Liz Carnabuci, […]

More


News - MedTech & Diagnostics

Department of Health halts PL changes as industry warns of device viability

Department of Health halts PL changes as industry warns of device viability

Health Industry Hub | August 7, 2026 |

The Department of Health has received the final evaluation report into the Prescribed List (PL) reforms from the Nous Group, […]

More


News - Biotechnology

argenx inks new agreement with Australian regenerative medicine biotech

Health Industry Hub | August 7, 2026 |

Immunology company argenx has entered into a new strategic partnership agreement with Monash University and Monash-originated spinout Myostellar, to develop […]

More


News - Pharmaceuticals

The human face rewriting Australia’s most common rare disease, cystic fibrosis

The human face rewriting Australia’s most common rare disease, cystic fibrosis

Health Industry Hub | August 7, 2026 |

New national data from the Australian Cystic Fibrosis Data Registry (ACFDR) has revealed a significant shift in the trajectory of […]

More


This content is copyright protected. Please subscribe to gain access.